Terms: = Skin cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF
178 results:
1. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract] [Full Text] [Related]
2. The role of craf in cancer progression: from molecular mechanisms to precision therapies.
Riaud M; Maxwell J; Soria-Bretones I; Dankner M; Li M; Rose AAN
Nat Rev Cancer; 2024 Feb; 24(2):105-122. PubMed ID: 38195917
[TBL] [Abstract] [Full Text] [Related]
3. Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
Louveau B; Reger De Moura C; Jouenne F; Sadoux A; Allayous C; Da Meda L; Bernard-Cacciarella M; Baroudjian B; Lebbé C; Mourah S; Dumaz N
Melanoma Res; 2024 Apr; 34(2):186-192. PubMed ID: 38141200
[TBL] [Abstract] [Full Text] [Related]
4. Spitz tumor with raf1 fusion: A report of 3 cases.
Donati M; Nosek D; Olivares S; Lemahieu J; Loontiens S; Mansour B; Gerami P; Kazakov DV
Ann Diagn Pathol; 2023 Dec; 67():152215. PubMed ID: 37856952
[TBL] [Abstract] [Full Text] [Related]
5. A phase I, single-center, open-label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [
Wollenberg L; Hahn E; Williams J; Litwiler K
Pharmacol Res Perspect; 2023 Oct; 11(5):e01140. PubMed ID: 37775918
[TBL] [Abstract] [Full Text] [Related]
6. Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition.
Martin SB; Polubothu S; Bruzos AL; Kelly G; Horswell S; Sauvadet A; Bryant D; Zecchin D; Riachi M; Michailidis F; Sadri A; Muwanga-Nanyonjo N; Lopez-Balboa P; Knöpfel N; Bulstrode N; Pittman A; Yeh I; Kinsler VA
J Invest Dermatol; 2024 Mar; 144(3):593-600.e7. PubMed ID: 37716647
[TBL] [Abstract] [Full Text] [Related]
7. miR-224-5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway.
Liu Y; Ruan H; Lu F; Peng H; Luan W
Pathol Res Pract; 2023 Sep; 249():154772. PubMed ID: 37611431
[TBL] [Abstract] [Full Text] [Related]
8. Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.
Najem A; Krayem M; Sabbah S; Pesetti M; Journe F; Awada A; Désaubry L; Ghanem GE
Cells; 2023 Jul; 12(14):. PubMed ID: 37508519
[TBL] [Abstract] [Full Text] [Related]
9. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib.
Tkacik E; Li K; Gonzalez-Del Pino G; Ha BH; Vinals J; Park E; Beyett TS; Eck MJ
J Biol Chem; 2023 May; 299(5):104634. PubMed ID: 36963492
[TBL] [Abstract] [Full Text] [Related]
10. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in
de Braud F; Dooms C; Heist RS; Lebbe C; Wermke M; Gazzah A; Schadendorf D; Rutkowski P; Wolf J; Ascierto PA; Gil-Bazo I; Kato S; Wolodarski M; McKean M; Muñoz Couselo E; Sebastian M; Santoro A; Cooke V; Manganelli L; Wan K; Gaur A; Kim J; Caponigro G; Couillebault XM; Evans H; Campbell CD; Basu S; Moschetta M; Daud A
J Clin Oncol; 2023 May; 41(14):2651-2660. PubMed ID: 36947734
[TBL] [Abstract] [Full Text] [Related]
11. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of craf and MEK1/2.
Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
[TBL] [Abstract] [Full Text] [Related]
12. Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the raf1 gene.
Boileau M; Descarpentries C; Delzenne G; Trentesaux V; Greliak A; Jamme P; Marchetti P; Mortier L
Melanoma Res; 2023 Jun; 33(3):247-251. PubMed ID: 36866640
[TBL] [Abstract] [Full Text] [Related]
13. Discovery of New Quinolone-Based Diarylamides as Potent B-RAF
Kim HJ; Park JW; Seo S; Cho KH; Alanazi MM; Bang EK; Keum G; El-Damasy AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834628
[TBL] [Abstract] [Full Text] [Related]
14. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
[TBL] [Abstract] [Full Text] [Related]
15. BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS
McGrail K; Granado-Martínez P; Esteve-Puig R; García-Ortega S; Ding Y; Sánchez-Redondo S; Ferrer B; Hernandez-Losa J; Canals F; Manzano A; Navarro-Sabaté A; Bartrons R; Yanes O; Pérez-Alea M; Muñoz-Couselo E; Garcia-Patos V; Recio JA
Nat Commun; 2022 Nov; 13(1):7113. PubMed ID: 36402789
[TBL] [Abstract] [Full Text] [Related]
16. Identification of fusions with potential clinical significance in melanoma.
Moran JMT; Le LP; Nardi V; Golas J; Farahani AA; Signorelli S; Onozato ML; Foreman RK; Duncan LM; Lawrence DP; Lennerz JK; Dias-Santagata D; Hoang MP
Mod Pathol; 2022 Dec; 35(12):1837-1847. PubMed ID: 35871080
[TBL] [Abstract] [Full Text] [Related]
17. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract] [Full Text] [Related]
18. Targeting EGFR, RSK1, raf1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study.
Bennani FE; Doudach L; Karrouchi K; Tarib A; Rudd CE; Ansar M; Faouzi MEA
J Biomol Struct Dyn; 2023 Jun; 41(9):4194-4218. PubMed ID: 35442150
[TBL] [Abstract] [Full Text] [Related]
19. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract] [Full Text] [Related]
20. MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells.
Estrada C; Mirabal-Ortega L; Méry L; Dingli F; Besse L; Messaoudi C; Loew D; Pouponnot C; Bertolotto C; Eychène A; Druillennec S
Commun Biol; 2022 Jan; 5(1):101. PubMed ID: 35091687
[TBL] [Abstract] [Full Text] [Related]
[Next]
